AZD 6918
Alternative Names: AZD6918Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Jul 2009 Discontinued - Phase-I for Solid tumours in USA (PO)